3854 related articles for article (PubMed ID: 16382131)
21. Combined, reduced-antigen content tetanus, diphtheria, and acellular pertussis vaccine (Boostrix): a review of its use as a single-dose booster immunization in individuals aged 10-64 years in the US.
Plosker GL
BioDrugs; 2009; 23(4):253-67. PubMed ID: 19697967
[TBL] [Abstract][Full Text] [Related]
22. Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine (Tdap) in pregnant women and persons who have or anticipate having close contact with an infant aged <12 months --- Advisory Committee on Immunization Practices (ACIP), 2011.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2011 Oct; 60(41):1424-6. PubMed ID: 22012116
[TBL] [Abstract][Full Text] [Related]
23. Assessment of nine candidate DTP-vaccines with reduced amount of antigen and/or without adjuvant as a fourth (booster-) dose in the second year of life.
Knuf M; Habermehl P; Faber J; Bock HL; Sänger R; Bogaerts H; Clemens R; Schuind A; du Prel JB; Schmitt HJ
Vaccine; 2006 Jul; 24(27-28):5627-36. PubMed ID: 16740348
[TBL] [Abstract][Full Text] [Related]
24. The safety of immunizing with tetanus-diphtheria-acellular pertussis vaccine (Tdap) less than 2 years following previous tetanus vaccination: Experience during a mass vaccination campaign of healthcare personnel during a respiratory illness outbreak.
Talbot EA; Brown KH; Kirkland KB; Baughman AL; Halperin SA; Broder KR
Vaccine; 2010 Nov; 28(50):8001-7. PubMed ID: 20875487
[TBL] [Abstract][Full Text] [Related]
25. Vaccination of adults 65 years of age and older with tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine (Boostrix(®)): results of two randomized trials.
Weston WM; Friedland LR; Wu X; Howe B
Vaccine; 2012 Feb; 30(9):1721-8. PubMed ID: 22212127
[TBL] [Abstract][Full Text] [Related]
26. An adolescent-adult formulation tetanus and diptheria toxoids adsorbed combined with acellular pertussis vaccine has comparable immunogenicity but less reactogenicity in children 4-6 years of age than a pediatric formulation acellular pertussis vaccine and diphtheria and tetanus toxoids adsorbed combined with inactivated poliomyelitis vaccine.
Langley JM; Predy G; Guasparini R; Law B; Diaz-Mitoma F; Whitstitt P; Tapiero B; Dionne M; Tomovici A; Mills E; Halperin SA
Vaccine; 2007 Jan; 25(6):1121-5. PubMed ID: 17045366
[TBL] [Abstract][Full Text] [Related]
27. Pertussis immunity and response to tetanus-reduced diphtheria-reduced pertussis vaccine (Tdap) after autologous peripheral blood stem cell transplantation.
Small TN; Zelenetz AD; Noy A; Rice RD; Trippett TM; Abrey L; Portlock CS; McCullagh EJ; Vanak JM; Mulligan AM; Moskowitz CH
Biol Blood Marrow Transplant; 2009 Dec; 15(12):1538-42. PubMed ID: 19896077
[TBL] [Abstract][Full Text] [Related]
28. Use of mass Tdap vaccination to control an outbreak of pertussis in a high school--Cook County, Illinois, September 2006-January 2007.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2008 Jul; 57(29):796-9. PubMed ID: 18650787
[TBL] [Abstract][Full Text] [Related]
29. Update on adolescent immunization: review of pertussis and the efficacy, safety, and clinical use of vaccines that contain tetanus-diphtheria-acellular pertussis.
Wilson TR
J Pediatr Health Care; 2006; 20(4):229-37. PubMed ID: 16831630
[TBL] [Abstract][Full Text] [Related]
30. Pertussis in adolescents and adults: should we vaccinate?
Lee GM; Lebaron C; Murphy TV; Lett S; Schauer S; Lieu TA
Pediatrics; 2005 Jun; 115(6):1675-84. PubMed ID: 15930232
[TBL] [Abstract][Full Text] [Related]
31. FDA approval of expanded age indication for a tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2011 Sep; 60(37):1279-80. PubMed ID: 21937974
[TBL] [Abstract][Full Text] [Related]
32. A randomised, double-blind, non-inferiority clinical trial on the safety and immunogenicity of a tetanus, diphtheria and monocomponent acellular pertussis (TdaP) vaccine in comparison to a tetanus and diphtheria (Td) vaccine when given as booster vaccinations to healthy adults.
Thierry-Carstensen B; Jordan K; Uhlving HH; Dalby T; Sørensen C; Jensen AM; Heilmann C
Vaccine; 2012 Aug; 30(37):5464-71. PubMed ID: 22776216
[TBL] [Abstract][Full Text] [Related]
33. Diphtheria-tetanus-acellular pertussis and inactivated poliovirus vaccines given separately or combined for booster dosing at 4-6 years of age.
Black S; Friedland LR; Ensor K; Weston WM; Howe B; Klein NP
Pediatr Infect Dis J; 2008 Apr; 27(4):341-6. PubMed ID: 18316985
[TBL] [Abstract][Full Text] [Related]
34. The preteen visit: an opportunity for prevention.
Campos-Outcalt D
J Fam Pract; 2006 Dec; 55(12):1054-6. PubMed ID: 17137541
[TBL] [Abstract][Full Text] [Related]
35. Persistence of antibodies 3 years after booster vaccination of adults with combined acellular pertussis, diphtheria and tetanus toxoids vaccine.
Weston W; Messier M; Friedland LR; Wu X; Howe B
Vaccine; 2011 Nov; 29(47):8483-6. PubMed ID: 21945698
[TBL] [Abstract][Full Text] [Related]
36. Tetanus-diphtheria-acellular pertussis vaccination of adults in the USA.
Gidengil CA; Sandora TJ; Lee GM
Expert Rev Vaccines; 2008 Jul; 7(5):621-34. PubMed ID: 18564017
[TBL] [Abstract][Full Text] [Related]
37. Shortened interval between tetanus vaccines.
Lodolce AE
Ann Pharmacother; 2012 Jun; 46(6):884-8. PubMed ID: 22669800
[TBL] [Abstract][Full Text] [Related]
38. Combined tetanus, diphtheria, and 5-component pertussis vaccine for use in adolescents and adults.
Pichichero ME; Rennels MB; Edwards KM; Blatter MM; Marshall GS; Bologa M; Wang E; Mills E
JAMA; 2005 Jun; 293(24):3003-11. PubMed ID: 15933223
[TBL] [Abstract][Full Text] [Related]
39. Immunogenicity and reactogenicity of co-administered tetanus-diphtheria-acellular pertussis (Tdap) and tetravalent meningococcal conjugate (MCV4) vaccines compared to their separate administration.
Weston WM; Friedland LR; Wu X; Howe B
Vaccine; 2011 Jan; 29(5):1017-22. PubMed ID: 21134450
[TBL] [Abstract][Full Text] [Related]
40. Immunogenicity and safety of a second booster dose of an acellular pertussis vaccine combined with reduced antigen content diphtheria-tetanus toxoids 10 years after a first booster in adolescence: An open, phase III, non-randomized, multi-center study.
Kovac M; Kostanyan L; Mesaros N; Kuriyakose S; Varman M
Hum Vaccin Immunother; 2018; 14(8):1977-1986. PubMed ID: 29630439
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
